Cash Flow Statement

Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation and Depletion Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Net Cash Flow Net Income Non-cash Items Other Working Capital Changes Share-based Compensation

Daily Values

Growth Metrics

Others

Ratios

Xilio Therapeutics (XLO) Change in Receivables (2024)

Historic Change in Receivables for Xilio Therapeutics (XLO) over the last 1 years, with Q1 2024 value amounting to $30.0 million.